Immuneering (IMRX) Stock Statistics & Valuation Metrics

Immuneering has a market cap or net worth of $344.16M. The enterprise value is $68.67M.

Immuneering has 64,569,970 shares outstanding. The number of shares has decreased by -2.65% in one year.

Immuneering’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -26.71%.

The current PE Ratio of Immuneering is ―. Immuneering’s PEG ratio is 0.14.

In the last 12 months, Immuneering had revenue of 0.00 and earned -56.02M in profits. Earnings per share was -1.27.

In the last 12 months, operating cash flow was -45.34M and capital expenditures -142.23K, giving a free cash flow of -45.49M billion.

Immuneering pays an annual dividend of ―, resulting in a dividend yield of ―

Immuneering upcoming earnings date is May 12, 2026, Before Open (Confirmed).

Immuneering as a current ratio of 17.50, with Debt / Equity ratio of 1.75%

In the past 12 months, Immuneering has paid 0.00 in taxes.

Immuneering EV to EBITDA ratio is -2.81, with an EV/FCF ratio of -3.62.

Immuneering has $172.83M in cash and marketable securities with $3.82M in debt, giving a net cash position of $169.01M billion.

Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.

The average price target for Immuneering is $14.33, which is 11.43% higher than the current price. The consensus rating is Strong Buy